Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (121-130 of 235) with videos related to

Pageof 24
Sort By:
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
JCO Precision Oncology|September 11, 2020
Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung AdenocarcinomasMatthew D Hellmann, Takuo Hayashi, Boris Reva, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
The Journal of Experimental Medicine|November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancerCamila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Pageof 24

Showing results (121-130 of 235) with videos related to

Sort By:
Pageof 24
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
JCO Precision Oncology|September 11, 2020
Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung AdenocarcinomasMatthew D Hellmann, Takuo Hayashi, Boris Reva, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
The Journal of Experimental Medicine|November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancerCamila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Pageof 24